Please login to the form below

Not currently logged in
Email:
Password:

Wilson Therapeutics

This page shows the latest Wilson Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Alexion adds to pipeline with $1.2bn Syntimmune buy

Alexion adds to pipeline with $1.2bn Syntimmune buy

In the meantime, however, it’s also been adding to its earlier-stage pipeline and the Syntimmune acquisition comes a few months after it snapped up Swedish biotech Wilson Therapeutics for ... $855m, adding orally-active copper binder WTX-101 in phase

Latest news

  • Abingworth raises $315m to expand hunt for promising biotechs Abingworth raises $315m to expand hunt for promising biotechs

    The acquisitions of rare disease specialist Wilson Therapeutics by Alexion for $855m and of IFM Therapeutics – an immuno-oncology player – by Bristol-Myers Squibb for $1.3bn are recent successes for ... Abingworth has shown it is prepared to back

  • Alexion adds to pipeline rebuild with $855m Wilson buy Alexion adds to pipeline rebuild with $855m Wilson buy

    Alexion Pharma’s drive to reduce its reliance on cash cow Soliris has gone up a gear with a $855m offer for rare disease company Wilson Therapeutics. ... Ludwig Hantson, Alexion’s chief executive, said: “The acquisition of Wilson Therapeutics is a

  • mRNA - message received mRNA - message received

    Arcturus Therapeutics. thrombopoietin; alpha-1 antitrypsin replacment; cystic fibrosis; iron disorders. Tekmira, Arrowhead. ... Shire. Eukarys. monogenic liver diseases; Wilson disease. Moderna Therapeutics. cancer; cardiovascular disease; infectious

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest appointments

  • IGEM Therapeutics appoints Dr Tim Wilson as CEO IGEM Therapeutics appoints Dr Tim Wilson as CEO

    IGEM Therapeutics appoints Dr Tim Wilson as CEO. He joins after the UK immuno-oncology firm raises £2m to advance its pipeline. ... Wilson has over 28 years’experience in the life sciences sector, ranging from venture capital and start-ups to

  • Therachon strengthens management team Therachon strengthens management team

    He currently serves as chairman of Asceneuron, Complix and InteRNA, and as a non-executive director at Hansa Medical, Sobi, Wilson Therapeutics and Dutch Top Sector Life Sciences and Health.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics